New product: Bekemv (eculizumab) 300 mg concentrate for solution for infusion

This biosimilar to Soliris is licensed for use in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria.

SPS commentary:

The originator product, Soliris, is also licensed for the treatment of:

Atypical haemolytic uremic syndrome.
Refractory generalised myasthenia gravis in patients who are anti-acetylcholine receptor.
Neuromyelitis optica spectrum disorder in patients who are anti-aquaporin-4 antibody-positive with a relapsing course of the disease.

electronic Medicines compendium